Article Text

Download PDFPDF
Outcomes and toxicity after salvage radiotherapy for vaginal relapse of endometrial cancer
  1. Lucas Gomes Sapienza1,2,
  2. Matthew S Ning3,
  3. Rosinda de la Pena4,
  4. Laura Kollar McNew5,
  5. Anuja Jhingran3,
  6. Larissa Georgeon6,
  7. Nabila Rasool4,
  8. Maria José Leite Gomes7,
  9. Eyad Abu-Isa5 and
  10. Glauco Baiocchi8
  1. 1 Radiation Oncology, Baylor College of Medicine, Houston, Texas, USA
  2. 2 Internal Medicine, Ascension Providence Hospital, Southfield, Michigan, USA
  3. 3 Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
  4. 4 Gynecologic Oncology, Ascension Providence Hospital, Southfield, Michigan, USA
  5. 5 Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
  6. 6 Michigan State University College of Human Medicine, East Lansing, Michigan, USA
  7. 7 Radiation Oncology, Hospital Federal dos Servidores do Estado (HSFE-RJ), Rio de Janeiro, Rio de Janeiro, Brazil
  8. 8 Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, São Paulo, Brazil
  1. Correspondence to Dr Lucas Gomes Sapienza, Radiation Oncology, Baylor College of Medicine, Houston, TX 77030, USA; lucasgsapienza{at}


Objectives Studies of salvage radiotherapy in locally recurrent endometrial cancer remain limited. The aim of this study was to evaluate the efficacy of salvage radiotherapy for vaginal relapse of endometrial cancer and to explore prognostic factors associated with outcomes.

Methods We evaluated 30 patients treated with salvage external-beam radiotherapy and/or vaginal brachytherapy for vaginal relapses of endometrial cancer between 2009 and 2018. The inclusion criteria were: pathologically-confirmed recurrence; loco-regional relapse (in absence of distant metastases); and salvage treatment including external-beam radiotherapy and/or vaginal brachytherapy. Outcomes were evaluated via Kaplan-Meier, with the log-rank test employed to compare differences among various groups and identify prognostic factors.

Results 30 patients developed vaginal recurrence at a median time of 20.6 months (range 2—219) post-hysterectomy. The most common site of recurrence was the vaginal apex (60%), followed by the distal vagina (10%). Salvage radiotherapy entailed combination external-beam radiotherapy and vaginal brachytherapy (n=24) or single modality treatment (n=6), along with concurrent chemotherapy in 20 cases. At a median follow-up of 4.4 years (range 0.1–130) post-radiotherapy, the 5 year rates of local control, regional control, metastasis-free interval, disease-free interval, and overall survival were 89%, 91.5%, 75.5%, 69%, and 83%, respectively. Factors associated with improved disease-free interval included: endometrioid histology (p=0.03), isolated vaginal relapse (p=0.003), late recurrence (>9 months) (p=0.007), and combined modality radiotherapy (p=0.001). The only factor associated with overall survival was isolated vaginal relapse (in the absence of other recurrent disease) (p=0.02). Regarding toxicity, 18% of patients experienced acute grade ≥3 events (most commonly gastrointestinal). The 5 year rates of rectal bleeding, small bowel obstruction, and pelvic fracture were 31%, 18%, and 13%, respectively.

Conclusions Salvage radiotherapy imparts excellent loco-regional control for vaginal relapses of endometrial cancer and should entail combination external-beam radiotherapy and vaginal brachytherapy. Patients should be closely monitored for late gastrointestinal toxicity following salvage radiotherapy.

  • endometrial neoplasms
  • radiotherapy
  • neoplasm recurrence, local

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @MDsapienza,, @glaucobaiocchi

  • Contributors All author have provided substantial contributions and are in agreement with all aspects of the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request. The de-identified study data will be available for investigators whose proposed use of the data has been approved by an independent review committee or for use in an individual participant data meta-analysis after providing study methodology.